Skip to Content

Investor Update

Basel, 11 June 2009

Reminder: Roche Investor Science Event: Conference call from EULAR 2009

Analyst briefing on new data presented on Actemra and MabThera at the EULAR Annual Meeting, Friday, June 12th  

We are pleased to invite you to a Conference Call to discuss new data on our Rheumatoid Arthritis portfolio being presented during the 2009 EULAR Conference (European League Against Rheumatism), which runs from June 10th – June 13th, 2009 in Copenhagen, Denmark.  

In addition, we have prepared an overview of oral and poster abstracts relevant to Roche and our partners, which can be downloaded from our website via URL http://www.roche.com/eular-planner-2009.pdf.

Conference Call Date/Time:Friday, 12th June, 2009
03.30 pm to 05.00 pm Central Europe Summer time CEST (Denmark/Basel)
02.30 pm to 04.00 pm British Summer time BST (London)
09.30 am to 11.00 am Eastern Daylight time EDT (United States)

The conference call will consist of a short presentation, followed by a Q&A session (with live access to speakers). Presentation slides will be posted prior to the event on the Roche IR website www.roche.com/ir_agenda.

Analysts are invited to dial in to the conference call using the following dial-in numbers:
+41 (0) 91 610 56 00 (Europe and ROW)
+44 (0) 207 107 06 11 (UK)
+1 (1) 866 291 4166 (USA-toll free)

A replay of the conference call will be available one hour after the conference call, for 48 hours. Access is by dialing:
+41 91 612 43 30 (Europe and ROW)
+44 207 108 62 33 (UK)
+1 (1) 866 416 25 58 (USA)

Listeners will be asked to enter the ID 14184 followed by the # sign

Highlights of the data to be presented during EULAR include:

  • Inhibition of joint damage and improved clinical outcomes with a combination of Rituximab (RTX) and methotrexate (MTX) in patients (pts) with early active rheumatoid arthritis (RA) who are naive to RTX: a randomised active comparator placebo-controlled trial (IMAGE) (Abstract OP-022; Oral presentation Thursday June 11th, 10:15-11:45, Auditorium 1)
  • Long-term safety of Rituximab: follow-up of the RA clinical trials and re-treatment population  (Abstract OP-026; Oral presentation Thursday June 11th, 10:15-11:45, Auditorium 1)
  • Autoantibody-positive rheumatoid arthritis (RA) patients (pts) have enhanced clinical response to rituximab (RTX) when compared with seronegative patients  (Abstract FRI0256; Poster session Friday June 12th, 11:45-1:30)
  • Tocilizumab Inhibits Structural Joint Damage, Improves Physical Function, and Increases DAS28 Remission Rates in RA Patients Who Respond Inadequately to Methotrexate: The LITHE Study (Abstract OP-0157; Oral presentation Friday June 12th, 10:15-11:45, Hall A2)
  • Efficacy of Tocilizumab (TCZ) VS Methotrexate (MTX) Monotherapy in Patients with Rheumatoid Arthritis (RA) with No Prior MTX or DMARD Exposure  (Abstract FRI0252; Poster session Friday June 12th, 11:45-1:30)
  • Safety and Tolerability of Tocilizumab in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA) and Inadequate Response to MTX: 1-year results of the LITHE Study  (Abstract FRI0262; Poster session Friday June 12th, 11:45-1:30)
  • Efficacy Of Tocilizumab (TCZ) In Rheumatoid Arthritis (RA): Interim Analysis Of Long-term Extension Trials Of Up To 2.5 Years  (Abstract FRI0133; Poster session Friday June 12th, 11:45-1:30)

We hope that you can participate in this event.